Are vaccinations recommended for people with pulmonary fibrosis? 

Vaccinations are strongly recommended for individuals living with pulmonary fibrosis because respiratory infections pose a significant risk to those with existing lung scarring. When the lungs are already compromised by fibrosis, an infection such as the flu or pneumonia can lead to a severe decline in respiratory function and may trigger an acute exacerbation of the disease. In the United Kingdom, the healthcare system prioritises people with chronic lung conditions for seasonal and routine immunisations to reduce the likelihood of hospitalisation. By keeping up to date with the recommended vaccination schedule, patients can provide their immune system with the tools needed to recognise and fight off dangerous pathogens before they cause further damage to delicate lung tissues. 

What We’ll Discuss in This Article 

• Why pulmonary fibrosis increases the risk of complications from common infections. 

• The annual flu vaccination programme and eligibility for respiratory patients. 

• Understanding the pneumococcal vaccine and the 2026 transition to PCV20. 

• Eligibility criteria for the Spring 2026 COVID-19 vaccination programme. 

• The role of the RSV vaccine for older adults with lung conditions. 

• How immunosuppressive treatments for fibrosis impact vaccination timing. 

• Practical steps for accessing free vaccinations through the NHS. 

The Importance of Infection Prevention in Lung Disease 

Infection prevention is a cornerstone of care for anyone diagnosed with an interstitial lung disease because the reserve capacity of the lungs is lower than in healthy individuals. When a virus or bacteria enters the respiratory tract, the body responds with inflammation, which can cause further scarring in a process that is often irreversible. For a person with healthy lungs, a case of the flu might result in a week of discomfort, but for someone with pulmonary fibrosis, it could lead to respiratory failure. The NHS recommends that people with long-term respiratory conditions like pulmonary fibrosis receive the flu vaccine every year to mitigate these severe risks. This preventative approach is designed to keep the patient as stable as possible and avoid the trauma of an emergency hospital admission. 

The vulnerability of the lungs in pulmonary fibrosis is not just about the scarring itself but also how the body handles the stress of an illness. Fever and infection increase the body’s demand for oxygen, forcing the already stressed lungs to work even harder. Furthermore, the inflammation associated with an infection can sometimes “trigger” the fibrotic process to accelerate, leading to a permanent drop in lung capacity. This is why medical professionals in the UK view vaccinations not as an optional extra but as a vital component of the overall treatment plan, standing alongside medications like antifibrotics and supplemental oxygen. 

The Annual Influenza Vaccination Programme 

The influenza virus changes every year, which is why a new vaccine is developed annually to match the circulating strains. For the 2025 to 2026 season, the NHS provides the flu vaccine free of charge to all adults with chronic respiratory diseases, including idiopathic pulmonary fibrosis. The vaccine is usually administered in the autumn, ideally before the virus begins to spread widely in the community during the winter months. Because the immune response takes about two weeks to fully develop, patients are encouraged to book their appointments as soon as the service becomes available in September or October. 

The flu vaccine used in the UK for adults is an inactivated or recombinant version, meaning it does not contain a live virus and cannot cause the flu itself. Some patients may experience a mild ache in the arm or a slight temperature after the injection, but these are signs that the immune system is responding to the vaccine. For those with pulmonary fibrosis, the small risk of a temporary side effect is significantly outweighed by the protection offered against a virus that can cause life-threatening pneumonia. If a patient is unable to attend a GP surgery, many local pharmacies also offer the service, making it highly accessible across the country. 

Pneumococcal Vaccination and the 2026 Transition 

The pneumococcal vaccine protects against a specific type of bacteria called Streptococcus pneumoniae, which is a leading cause of bacterial pneumonia, meningitis, and sepsis. Unlike the flu vaccine, the pneumococcal vaccine is not required every year for most people. Historically, the UK has used the PPV23 vaccine for adults in clinical risk groups, with a single dose often providing long-term protection. However, pneumococcal vaccination is essential for protecting against infections like pneumonia, which can worsen lung scarring, and some individuals with specific immune concerns may require a booster every five years. 

In early 2026, the UK vaccination programme is undergoing a significant transition as the PCV20 vaccine begins to replace the older PPV23 version for many adults. PCV20 is a conjugate vaccine that provides a broader and more robust immune response against more strains of the bacteria. This update is particularly beneficial for those with chronic lung conditions, as it offers enhanced protection during the years when the immune system might naturally weaken. Patients who have already received a pneumococcal vaccine in the past should speak with their respiratory team to see if they require the new version or if their current protection remains sufficient under the new 2026 guidelines. 

COVID-19 Vaccination Strategy in 2026 

The strategy for COVID-19 vaccination has evolved into a targeted seasonal programme focused on those at the highest risk of severe illness. As of early 2026, the NHS continues to offer booster doses during the autumn and spring to specific groups. The Spring 2026 COVID-19 programme provides additional protection for those who are most vulnerable due to age or a weakened immune system. While pulmonary fibrosis is a serious condition, eligibility for a COVID-19 booster often depends on age, such as being 75 or older, or whether the patient is taking certain medications that suppress the immune system. 

Many patients with pulmonary fibrosis are prescribed antifibrotic medications like nintedanib or pirfenidone, which do not typically suppress the immune system significantly. However, some individuals may also be taking corticosteroids like prednisolone or other immunosuppressants like mycophenolate mofetil. If you are on these types of medications, you may be classified as immunosuppressed and therefore eligible for more frequent COVID-19 vaccinations. The goal of these boosters is to “top up” the antibodies that naturally fade over time, ensuring that if exposure occurs, the body can fight the virus effectively and avoid a severe respiratory episode. 

Managing Vaccinations and Immunosuppressive Therapy 

One of the most common questions for people with pulmonary fibrosis is whether their medication will interfere with how well a vaccine works. For those taking immunosuppressants, the immune system might not produce as many antibodies in response to a vaccine compared to someone not taking those drugs. However, this does not mean the vaccine is ineffective or unsafe. In fact, it often makes the vaccine even more necessary because the person is at a higher risk of catching an infection in the first place. 

The timing of the vaccine can sometimes be adjusted to maximise its effectiveness. For example, if a patient is about to start a new course of high-dose steroids or a different immunosuppressant, the doctor might suggest having the vaccinations a few weeks before the treatment begins. Most vaccines used in the UK for adults are “killed” or “inactivated,” which means they are safe for people with weakened immune systems. Live vaccines, such as some versions of the shingles or yellow fever vaccine, may need to be avoided or replaced with an inactivated version, so it is vital to disclose all current medications to the person administering the jab. 

Accessing Vaccinations through the NHS 

Accessing vaccinations in the UK is a straightforward process, but it does require some proactivity on the part of the patient. Most people will receive an invitation from their GP surgery via text, email, or letter when they become eligible for a seasonal vaccine. However, if you have recently been diagnosed with pulmonary fibrosis and haven’t received an invitation, you should contact your surgery to ensure your medical records reflect your “at-risk” status. This ensures you are automatically included in future call-recall lists for the flu and pneumococcal programmes. 

For the COVID-19 and flu vaccines, the National Booking Service is often available online or via the 111 telephone service, allowing you to choose a time and location that is convenient for you. Many community pharmacies are now central to the delivery of these services, often offering walk-in appointments. When attending your appointment, it is a good idea to bring a list of your current medications and your latest clinic letter from your respiratory consultant. This allows the vaccinator to confirm your eligibility and answer any specific questions you might have about the injection and your lung condition. 

Conclusion 

Vaccinations are a critical and recommended part of the management plan for anyone living with pulmonary fibrosis in the UK. By staying protected against flu, pneumonia, COVID-19, and RSV, patients can significantly reduce the risk of life-threatening complications and disease exacerbations. These preventative measures help preserve lung function and support long-term stability in a condition that requires careful oversight. If you experience severe, sudden, or worsening symptoms, call 999 immediately. 

Authority Snapshot (E-E-A-T Block) 

This article provides up-to-date guidance on the vaccination requirements for pulmonary fibrosis patients within the UK healthcare system. The content has been curated by our medical content team and reviewed by Dr. Stefan Petrov to ensure alignment with NHS, NICE, and UK government standards for 2026. Our focus is on providing medically safe, practical education to help patients protect their respiratory health through evidence-based immunisation.